Literature DB >> 28501118

Impact of chromogranin A, differentiation, and mitoses in nonfunctional pancreatic neuroendocrine tumors ≤ 2 cm.

Katelin A Mirkin1, Christopher S Hollenbeak2, Joyce Wong3.   

Abstract

BACKGROUND: Small pancreatic neuroendocrine tumors (PNETs) are a unique subset of pancreatic neoplasms. Chromogranin A (CgA) levels, mitotic rate, and histologic differentiation are often used to characterize PNET behavior. This study evaluates the impact of these factors on survival in patients with PNETs.
METHODS: The US National Cancer Data Base (1998-2012) was reviewed for patients with stages I-III, nonfunctional PNETs ≤2 cm. Clinicopathologic characteristics were collected, and univariate and multivariate survival analyses were performed.
RESULTS: Of 1159 patients, 872 had tumor differentiation recorded, 403 had mitotic rate, and 217 patients had CgA. Mitotic rate >20 mitoses per 10 high-power microscopic fields was significantly associated with survival (hazard ratio [HR] = 10.6, P = 0.002) in multivariate analysis. Of those who underwent resection, there was no significant difference in positive lymph nodes between high (>100 ng/mL) and low (≤100 ng/mL) CgA levels (0.27 versus 0.37, P = 0.4440). Multivariate analyses of patients with both grade and CgA recorded found poorly differentiated tumors and very high CgA (>400 ng/mL) negatively impacted survival (HR = 2.99, P < 0.0001, HR = 3.47, P < 0.0001, respectively). Propensity score matching demonstrated improved 5-y survival in patients who underwent surgical resection, P < 0.0001.
CONCLUSIONS: Poorly differentiated disease should be considered an indicator of worse prognosis in nonfunctional PNETs ≤2 cm. Surgical resection appears to improve survival in these patients.
Copyright © 2016 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Chromogranin A; Mitotic rate; Pancreatic neuroendocrine tumor; Tumor differentiation

Mesh:

Substances:

Year:  2016        PMID: 28501118     DOI: 10.1016/j.jss.2016.12.033

Source DB:  PubMed          Journal:  J Surg Res        ISSN: 0022-4804            Impact factor:   2.192


  5 in total

1.  Predictive Value of Chromogranin A and a Pre-Operative Risk Score to Predict Recurrence After Resection of Pancreatic Neuroendocrine Tumors.

Authors:  Alexander V Fisher; Alexandra G Lopez-Aguiar; Victoria R Rendell; Courtney Pokrzywa; Flavio G Rocha; Zaheer S Kanji; George A Poultsides; Eleftherios A Makris; Mary E Dillhoff; Eliza W Beal; Ryan C Fields; Roheena Z Panni; Kamran Idrees; Paula Marincola Smith; Clifford S Cho; Megan V Beems; Shishir K Maithel; Emily R Winslow; Daniel E Abbott; Sharon M Weber
Journal:  J Gastrointest Surg       Date:  2019-01-18       Impact factor: 3.452

Review 2.  Prognostic and predictive factors on overall survival and surgical outcomes in pancreatic neuroendocrine tumors: recent advances and controversies.

Authors:  Lingaku Lee; Tetsuhide Ito; Robert T Jensen
Journal:  Expert Rev Anticancer Ther       Date:  2019-11-27       Impact factor: 4.512

3.  Preoperative serum chromogranin-a is predictive of survival in locoregional jejuno-ileal small bowel neuroendocrine tumors.

Authors:  Praveen D Chatani; John G Aversa; James D McDonald; Tahsin M Khan; Xavier M Keutgen; Naris Nilubol
Journal:  Surgery       Date:  2021-04-02       Impact factor: 4.348

4.  Limited role of Chromogranin A as clinical biomarker for pancreatic neuroendocrine tumors.

Authors:  Alessandra Pulvirenti; Deepthi Rao; Caitlin A Mcintyre; Mithat Gonen; Laura H Tang; David S Klimstra; Martin Fleisher; Lakshmi V Ramanathan; Diane Reidy-Lagunes; Peter J Allen
Journal:  HPB (Oxford)       Date:  2018-10-23       Impact factor: 3.647

5.  Establishment and Investigation of a Multiple Gene Expression Signature to Predict Long-Term Survival in Pancreatic Cancer.

Authors:  Zhiqiang Zhang; Jiangning Gu; Menghong Yin; Di Wang; Chi Ma; Jian Du; Zhikun Lin; Siling Hu; Xuelong Wang; Ying Li; Guang Tan; Haifeng Luo; Gang Wei
Journal:  Biomed Res Int       Date:  2020-09-15       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.